Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2005 1
2008 2
2009 3
2010 6
2011 2
2012 2
2013 7
2014 2
2016 2
2017 2
2018 4
2019 2
2020 6
2021 6
2022 14
2023 13
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Results by year

Filters applied: . Clear all
Page 1
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM; FIGARO-DKD Investigators. Pitt B, et al. N Engl J Med. 2021 Dec 9;385(24):2252-2263. doi: 10.1056/NEJMoa2110956. Epub 2021 Aug 28. N Engl J Med. 2021. PMID: 34449181 Clinical Trial.
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis.
Rossing P, Anker SD, Filippatos G, Pitt B, Ruilope LM, Birkenfeld AL, McGill JB, Rosas SE, Joseph A, Gebel M, Roberts L, Scheerer MF, Bakris GL, Agarwal R; FIDELIO-DKD and FIGARO-DKD Investigators. Rossing P, et al. Diabetes Care. 2022 Dec 1;45(12):2991-2998. doi: 10.2337/dc22-0294. Diabetes Care. 2022. PMID: 35972218 Free PMC article. Clinical Trial.
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis.
Agarwal R, Tu W, Farjat AE, Farag YMK, Toto R, Kaul S, Lawatscheck R, Rohwedder K, Ruilope LM, Rossing P, Pitt B, Filippatos G, Anker SD, Bakris GL; FIDELIO-DKD and FIGARO-DKD Investigators. Agarwal R, et al. Ann Intern Med. 2023 Dec;176(12):1606-1616. doi: 10.7326/M23-1023. Epub 2023 Dec 5. Ann Intern Med. 2023. PMID: 38048573 Clinical Trial.
Right atrium crossover.
Brito J, Plácido R, Matos P. Brito J, et al. Among authors: matos p. Eur Heart J Case Rep. 2023 Dec 26;8(1):ytad642. doi: 10.1093/ehjcr/ytad642. eCollection 2024 Jan. Eur Heart J Case Rep. 2023. PMID: 38213870 Free PMC article. No abstract available.
Occupational leg edema-use of compression stockings.
Guedes PM, Saldanha NA, Matos PM, Carvalho FS, Veiga G, Norton P. Guedes PM, et al. Among authors: matos pm. Porto Biomed J. 2020 Nov 24;5(6):e093. doi: 10.1097/j.pbj.0000000000000093. eCollection 2020 Nov-Dec. Porto Biomed J. 2020. PMID: 33283063 Free PMC article. Review.
Fracture of the fabella with radiologic and MRI.
Buruian A, Pinheiro V, Fonseca F, Matos P. Buruian A, et al. Among authors: matos p. BMJ Case Rep. 2023 Nov 30;16(11):e251811. doi: 10.1136/bcr-2022-251811. BMJ Case Rep. 2023. PMID: 38035674 Free PMC article.
Cutaneous metastases revealing a second hidden neoplasm.
De Matos PR, Silva M, Nogueira A, Pacheco J, Azevedo F. De Matos PR, et al. Dermatol Online J. 2023 Apr 15;29(2). doi: 10.5070/D329260785. Dermatol Online J. 2023. PMID: 37220301 No abstract available.
Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review.
de Matos PH, da Silva TP, Mansano AB, Gancedo NC, Tonin FS, Pelloso FC, Petruco MV, de Melo EB, Fernandez-Llimos F, Sanches ACC, de Mello JCP, Chierrito D, de Medeiros Araújo DC. de Matos PH, et al. Inflamm Res. 2022 Dec;71(12):1489-1500. doi: 10.1007/s00011-022-01642-7. Epub 2022 Oct 28. Inflamm Res. 2022. PMID: 36307652 Free PMC article. Review.
70 results